The Personalized Cancer Vaccine That Just Succeeded in Phase 3
The Personalized Cancer Vaccine That Just Succeeded in Phase 3 One Patient at a Time: How Merck and Moderna turned a patient’s own tumour mutations into an individualized mRNA therapy — and took it through a successful Phase 3 trial. ⏱ In 30 Seconds ✓ Intismeran autogene is made individually from mutations identified in each patient’s tumour. ✓ Its mRNA can encode up to 34 patient-specific neoantigens to help generate tumour-specific T-cell responses. ✓ Combined with pembrolizumab (Keytruda), it has now met the primary endpoint in a large Phase 3 melanoma trial . ✓ The full Phase 3 effect size and overall-survival results have not yet been reported. The trial was designed to follow patients for years, but on August 19, 2026, Merck and Moderna announced that a prespecified interim analysis had already provided an important answer. Their individualized mRNA cancer treatment, intismeran autogene , combined with pembrolizumab (Keytruda), had met the primary endpo...